Transforming Growth Factor-beta (TGF-β) signaling represents a critical pathway in regulating neuroinflammation, neurogenesis, and cellular survival in the adult brain. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4-repeat (4R) tauopathies, dysregulation of TGF-β signaling contributes to the progressive neurodegeneration characteristic of these disorders. This section examines the role of TGF-β pathway alterations in CBS/PSP pathogenesis and explores therapeutic implications. [1]
CBS and PSP share common pathological features of 4R tau accumulation, but exhibit distinct clinical presentations 1. While CBS presents with asymmetric cortical dysfunction and basal ganglia degeneration leading to apraxia, alien limb phenomena, and cortical sensory loss, PSP is characterized by vertical gaze palsy, postural instability, and axial rigidity with progressive gait disturbance. TGF-β signaling interacts with tau pathology through multiple mechanisms, including regulation of tau phosphorylation, modulation of neuroinflammation, and control of neuronal survival pathways. Understanding these interactions may reveal novel therapeutic targets for disease modification. [2]
The TGF-β pathway's complex role in neurodegeneration reflects its pleiotropic nature—a single pathway can exert both protective and harmful effects depending on cellular context, ligand concentration, and disease stage. This complexity makes TGF-β an attractive but challenging therapeutic target. [3]
The TGF-β family includes multiple ligands and receptors with distinct functions 2: [4]
TGF-β Isoforms: [5]
Receptor Types: [6]
In the central nervous system, TGF-β signaling regulates glial cell function, neuronal survival, and inflammatory responses through both canonical Smad-dependent and non-Smad signaling pathways. [7]
The canonical TGF-β pathway signals through Smad proteins: [8]
Receptor-activated Smads (R-Smads): Smad2 and Smad3 mediate canonical TGF-β signaling, while Smad1/5/8 mediate BMP signaling [9]
Co-Smad: Smad4 partners with R-Smads to form transcriptional complexes that translocate to the nucleus [10]
Inhibitory Smads: Smad6 and Smad7 provide negative feedback by blocking R-Smad phosphorylation and promoting receptor degradation
TGF-β also signals through non-Smad pathways:
These non-canonical pathways contribute to the diverse biological effects of TGF-β in the brain.
TGF-β signaling exerts neuroprotective effects through multiple mechanisms 3:
These protective effects make TGF-β essential for neuronal survival in the adult brain, particularly in regions susceptible to neurodegenerative processes.
TGF-β plays a dual, context-dependent role in neuroinflammation 4:
The balance between these opposing effects determines whether TGF-β promotes or ameliorates neuroinflammation in disease states.
TGF-β signaling regulates adult neurogenesis through 5:
TGF-β's effects on neurogenesis are particularly relevant to tauopathies, where impaired neurogenesis may limit the brain's capacity to replace lost neurons.
TGF-β signaling regulates all major glial cell types:
Studies demonstrate TGF-β pathway alterations in CBS/PSP 6:
The motor cortex and basal ganglia, regions prominently affected in CBS, show particular TGF-β pathway alterations. Immunohistochemical studies demonstrate increased TGF-β1 immunoreactivity in glial cells surrounding tau-positive neurons.
TGF-β signaling interacts with tau pathology in complex and sometimes contradictory ways 7:
The relationship between TGF-β and tau creates feedback loops that may accelerate disease progression. Increased TGF-β in response to tau pathology may initially serve a protective function but become maladaptive over time.
The pattern of TGF-β dysregulation in CBS/PSP follows the regional distribution of tau pathology:
Therapeutic strategies targeting TGF-β signaling include 8:
Challenges in TGF-β-targeted therapy 9:
Promising approaches include:
Given the complex pathophysiology of CBS/PSP, TGF-β-targeted therapies may be most effective in combination:
Dickson DW. Neuropathology of non-Alzheimer degenerative disorders. Journal of Internal Medicine. 2020. ↩︎
Armstrong MJ, et al. 'Corticobasal syndrome: a review of clinical features and diagnosis'. Neuropsychologia. 2020. ↩︎
Litvan I, et al. [ Clinical features and management of corticobasal syndrome](https://doi.org/10.1016/S1474-4422(20). Lancet Neurology. 2020. ↩︎
Boxer AL, et al. 'Comparison of PSP and CBS phenotypes: a prospective imaging study'. Neurology. 2020. ↩︎
Kovacs GG, et al. Staging of tau pathology in PSP. Acta Neuropathologica. 2022. ↩︎
Williams DR, et al. 'Tau pathology in PSP: burden and distribution'. Brain. 2021. ↩︎
Stamelou M, et al. Motor phenotypes and biomarkers in tauopathies. Neurobiology of Aging. 2021. ↩︎
Chahine LM, et al. Biomarkers for tauopathies in CBS/PSP. Neurobiology of Aging. 2020. ↩︎
Jellinger KA. 'Functional neuropathology of PSP: neural network dysfunction'. Acta Neuropathologica. 2020. ↩︎
Mandelkow EM, et al. Tau pathology and neurodegeneration. Journal of Alzheimer's Disease. 2010. ↩︎